Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma

European Journal of Haematology

Volumn 75, Issue 5, 2005, Pages 376-383

  Terpos, Evangelos ^a   Rezvani, Katayoun ^b   Basu, Supratik ^c   Milne, Alison E ^d   Rose, Peter E ^e   Scott, Geoffrey L ^f   Rahemtulla, Amin ^a   Samson, Diana ^a   Apperley, Jane F ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c Royal Wolverhampton Hospitals   (United Kingdom)

^d NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^e WARWICK HOSPITAL   (United Kingdom)

^f BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Multiple myeloma; Plasmacytoma; Relapse; Transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GLUTARALDEHYDE; IDARUBICIN; LOMUSTINE; MELPHALAN; METHYLPREDNISOLONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE TUMOR; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL; RECTUM TUMOR; SKIN TUMOR; TESTIS TUMOR;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLONE CELLS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA; RADIOTHERAPY, ADJUVANT; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; THALIDOMIDE;

EID: 26844527633     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00531.x     Document Type: Article

References (38)

1. GAHRTON G, TURA S, LJUNGMAN P, BLADE J, CAVO M, DE LAURENZI A, FACON T, GRATWOHL A, MICHALLET M, NIKOSKELAINEN J. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995;13:1312-1322.
2. GAHRTON G, SVENSSON H, CAVO M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001;113:209-216.
3. ATTAL M, HAROUSSEAU JL, STOPPA AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97.
4. CHILD JA, MORGAN GJ, DAVIES FE, OWEN RG, BELL SE, HAWKINS K, BROWN J, DRAYSON MT, SELBY PJ. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
5. TERPOS E, APPERLEY JF, SAMSON D, GILES C, CRAWLEY C, KANFER E, OLAVARRIA E, GOLDMAN JM, RAHEMTULLA A. Autologous stem cell transplantation in multiple myeloma: improved survival in non-secretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant 2003;31:163-170.
6. BLADE J, SAMSON D, REECE D, APPERLEY J, BJORKSTRAND B, GAHRTON G, GERTZ M, GIRALT S, JAGANNATH S, VESOLE D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
7. SANFRUCTUOSO C, CABALLERO MD, GARCIA-SANZ R, VIDRIALES B, VAZQUEZ L, SAN MIGUEL JF. Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation. Eur J Haematol 1996;56:181-183.
8. VEINSTEIN A, BRIZARD A, RANDRIAMALALA E, BABIN P, PREUD'HOMME JL, GUILHOT F. Central nervous system relapses after autologous stem cell transplantation for myeloma. Report of two cases. Hematol Cell Ther 1997;39:327-330.
9. KAHR WH, AL-HOMADHI A, MEHARCHAND J, BAILEY DJ, STEWART AK. Testicular plasmacytoma following chemical orchiectomy: potential role of hypogonadism in myeloma proliferation. Leuk Lymphoma 1998;28:437-442.
10. ZOMAS A, STEFANOUDAKI K, FISFIS M, PAPADAKI T, MEHTA J. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas. Bone Marrow Transplant 1998;21:1163-1165.
11. VAN DER GRIEND R, VERDONCK LF, PETERSEN EJ, VEENHUIZEN P, BLOEM AC, LOKHORST HM. Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999;23:195-197.
12. RONDELLI D, BANDINI G, CAVO M, RE F, MOTTA MR, SENESE B, LEOPARDI G, STANZANI M, TURA S. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case report. Bone Marrow Transplant 1999;24:685-687.
13. TRULLEMANS F, SCHOTS R, STORME G, CAMP BV. Late and localized extramedullary relapse of a light chain kappa myeloma after syngeneic bone marrow transplantation. Bone Marrow Transplant 2000;25:115-117.
14. CHONG G, BYRNES G, SZER J, GRIGG A. Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant 2000;26:1011-1015.
15. ALEGRE A, GRANDA A, MARTINEZ-CHAMORRO C, et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica 2002;87:609-614.
16. ROSENBLUM MD, BREDESON CN, CHANG CC, RIZZO JD. Subcutaneous plasmacytomas with tropism to sites of previous trauma in a multiple myeloma patient treated with an autologous bone marrow transplant. Am J Hematol 2003;72:274-277.
17. BYRNE JL, FAIRBAIRN J, DAVY B, CARTER IG, BESSELL EM, RUSSELL NH. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. Bone Marrow Transplant 2003;31:157-161.
18. ZEISER R, DESCHLER B, BERTZ H, FINKE J, ENGELHARDT M. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 2004;34:1057-1065.
19. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757.
20. LOKHORST HM, MEUWISSEN OJ, VERDONCK LF, DEKKER AW. High-risk multiple myeloma treated with high-dose melphalan. J Clin Oncol 1992;10:47-51.
21. MOREAU P, BATAILLE R, MAHE B, MILPIED N, HAROUSSEAU JL. High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma. J Clin Oncol 1993;11:1832 (letter).
22. BIAGI JJ, PRINCE HM. Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation. Br J Haematol 2001;115:484-485.
23. DAMAJ G, MOHTY M, VEY N, DINCAN E, BOUABDALLAH R, FAUCHER C, STOPPA AM, GASTAUT JA. Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. Eur J Haematol 2004;73:402-406.
24. FASSAS AB, MUWALLA F, BERRYMAN T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestation. Br J Haematol 2002;117:103-108.
25. PATRIARCA F, PROSDOCIMO S, TOMADINI V, VASCIAVEO A, BRUNO B, FANIN R. Efficacy of bortezomib therapy for extramedullary relapse of myeloma following autologous and nonmyeloablative allogeneic transplantation. Haematologica 2005;90:278-279 (Letter).
26. TRICOT G, VESOLE DH, JAGANNATH S, HILTON J, MUNSHI N, BARLOGIE B. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196-1198.
27. VERDONCK LF, LOKHORST HM, DEKKER AW, NIEUWENHUIS HK, PETERSEN EJ. Graft-versus-myeloma effect in two cases. Lancet 1996;347:800-801.
28. BERTZ H, BURGER JA, KUNZMANN R, MERTELSMANN R, FINKE J. Adoptive immuno-therapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997;11:281-283.
29. PEREZ-SIMON J, CABALLERO D, MATEOS M, MIGUEL JS. Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation. Leuk Lymphoma 2004;45:1725-1729.
30. SINGHAL S, MEHTA J, DESIKAN R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
31. JULIUSSON G, CELSING F, TURESSON I, LENHOFF S, ADRIANSSON M, MALM C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000;109:89-96.
32. KNELLER A, RAANANI P, HARDAN I, AVIGDOR A, LEVI I, BERKOWICZ M, BEN-BASSAT I. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug. Br J Haematol 2000;108:391-393.
33. BLADE J, PERALES M, ROSINOL L, et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001;113:422-424.
34. ROSINOL L, CIBEIRA MT, BLADE J, ESTEVE J, AYMERICH M, ROZMAN M, SEGARRA M, CID MC, FILELLA X, MONTSERRAT E. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004;89:832-836.
35. BIAGI JJ, MILESHKIN L, GRIGG AP, WESTERMAN DW, PRINCE HM. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001;28:1145-1150.
36. LENTZSCH S, LEBLANC R, PODAR K, DAVIES F, LIN B, HIDESHIMA T, CATLEY L, STIRLING DI, ANDERSON KC. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003;17:41-44.
37. KUMAR S, FONSECA R, DISPENZIERI A, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003;101:1715-1717.
38. RICHARDSON PG, BARLOGIE B, BERENSON J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.